year
respiratori
virus
account
signific
morbid
mortal
worldwid
furthermor
virus
influenza
b
parainfluenza
piv
respiratori
syncyti
viru
rsv
adenoviru
adv
often
caus
sever
manifest
immunocompromis
individu
includ
solid
organ
transplant
recipi
sotr
influenza
infect
known
caus
signific
morbid
mortal
immunocompromis
well
immunocompet
popul
fewer
data
virus
caus
respiratori
infect
sotr
recent
decad
effect
sustain
immunosuppress
therapi
develop
incorpor
antireject
regimen
decreas
incid
degre
reject
episod
popul
howev
simultan
enhanc
immunosuppress
increas
risk
infect
includ
due
respiratori
virus
report
rate
respiratori
viru
infect
rvi
among
sotr
vari
wide
literatur
exampl
among
lung
sotr
incid
rvi
publish
report
rang
like
due
heterogen
type
patient
screen
includ
whether
patient
symptomat
asymptomat
time
screen
furthermor
studi
may
select
case
sever
diseas
includ
hospit
patient
seen
healthcar
provid
outpati
set
patient
milder
respiratori
symptom
may
less
inclin
seek
medic
attent
anoth
problem
even
hospit
respiratori
infect
may
undergo
appropri
procedur
make
diagnosi
recent
identifi
specif
respiratori
pathogen
difficult
given
similar
clinic
present
among
potenti
pathogen
timeconsum
natur
avail
microbiolog
techniqu
cell
cultur
serolog
assay
molecular
diagnost
avail
laboratori
provid
rapid
reliabl
diagnos
compar
older
techniqu
includ
antigen
detect
addit
molecular
diagnost
led
identif
respiratori
tract
virus
previous
recogn
common
import
pathogen
includ
instanc
bocaviru
certain
enterovirus
coronavirus
despit
rel
dearth
knowledg
rvi
sotr
sever
studi
reveal
import
inform
asid
perhap
piv
rvi
sotr
tend
parallel
season
natur
infect
immunocompet
howev
sotr
may
atyp
present
includ
symptom
onset
subsequ
progress
sever
lifethreaten
diseas
sotr
may
also
shed
viru
prolong
period
time
even
absenc
symptom
thu
spread
virus
nosocomi
greater
degre
potenti
devast
consequ
hospit
sotr
coinfect
bacteria
fungi
also
commonli
seen
transplant
recipi
rvi
despit
seriou
consequ
rvi
immunocompromis
host
us
fdaapprov
therapi
avail
even
import
identifi
presenc
specif
virus
determin
antivir
therapi
may
benefit
patient
addit
decreas
immunosuppress
may
feasibl
order
speed
resolut
viral
infect
appropri
isol
precaut
must
institut
hospit
set
limit
spread
note
molecular
diagnost
mainstay
diagnosi
rvi
multiplex
polymeras
chain
reaction
pcr
assay
use
multipl
primer
pair
detect
varieti
differ
target
sequenc
effici
costeffect
mean
diagnosi
note
preikasa
et
al
recent
demonstr
feasibl
patientcollect
nasopharyng
swab
diagnosi
rvi
sotr
compar
sotr
lung
transplant
recipi
uniqu
suscept
respiratori
viral
infect
due
direct
exposur
allograft
pathogen
well
impair
mucociliari
function
lymphat
drainag
cough
reflex
due
denerv
allograft
addit
respiratori
viral
infect
thought
risk
factor
develop
reject
andor
bronchiol
obliteran
syndrom
bo
among
lung
sotr
although
consist
demonstr
literatur
cohort
lung
transplant
recipi
rvi
without
rvi
follow
month
demonstr
acut
reject
rate
rvi
group
compar
without
rvi
greater
declin
forc
expiratori
volum
rvi
group
howev
pool
analysi
vu
et
al
unabl
confirm
link
acut
reject
rvi
suffici
number
assess
associ
rvi
bo
mccurdyet
al
report
associ
rvi
treat
ribavirin
rbv
bo
fuehner
et
al
howev
found
protect
effect
rbv
treatment
among
lung
sotr
receiv
drug
paramyxoviru
infect
bo
among
rbv
recipi
bo
among
nonrbv
recipi
p
final
recent
prospect
cohort
studi
lung
transplant
recipi
demonstr
rvi
significantli
associ
acut
reject
declin
lung
function
month
definit
assess
associ
rvi
acut
chronic
reject
requir
studi
larger
cohort
patient
sinc
rvi
may
overlap
clinic
present
may
caus
upper
respiratori
tract
infect
urti
well
lrti
effort
made
identifi
caus
pathogen
treatment
option
avail
differ
viru
gener
sotr
suspect
rvi
nasopharyng
swab
wash
aspir
obtain
sent
rapid
test
ideal
pcrbase
assay
use
nucleic
acid
amplif
detect
broad
rang
respiratori
pathogen
cultur
antigen
detect
serolog
larg
replac
sensit
pcr
method
multiplex
pcr
wide
use
transplant
center
identifi
varieti
pathogen
detect
convent
method
may
vari
sensit
specif
detect
adv
quantit
adv
pcr
blood
may
also
obtain
aid
diagnosi
featur
possibl
pharmacolog
therapi
import
noninfluenza
rvi
sotr
popul
discuss
summar
tabl
adv
nonenvelop
doublestrand
dna
viru
serotyp
classifi
subgroup
adv
caus
varieti
usual
selflimit
infect
manifest
immunocompet
individu
adv
common
children
immunocompet
immunocompromis
popul
certain
adv
serotyp
predilect
caus
pulmonari
infect
includ
subgroup
serotyp
serotyp
c
serotyp
e
serotyp
immunocompromis
patient
becom
ill
newli
acquir
infect
reactiv
latent
viru
prior
infect
adv
infect
sotr
typic
occur
within
first
year
transplant
tend
caus
frequent
sever
diseas
lung
transplant
recipi
humar
et
al
report
find
adv
sotr
although
none
lung
transplant
recipi
viremia
univers
asymptomat
patient
cohort
recov
infect
consequ
cohort
lung
transplant
recipi
report
incid
adv
infect
asymptomat
associ
reject
declin
pulmonari
function
howev
other
report
pediatr
adult
sotr
sever
necrot
pneumonia
figur
advassoci
mortal
patient
receiv
antilymphocyt
antibodi
increas
risk
develop
adv
infect
increas
advspecif
lymphocyt
associ
resolut
adv
blood
lung
fdaapprov
antivir
treatment
adv
infect
therefor
mainstay
therapi
adv
pneumonia
reduct
immunosuppress
support
care
howev
cidofovir
cytosin
analog
interrupt
adv
replic
vitro
often
use
treatment
sever
infect
intracellular
diphosph
form
cidofovir
act
adv
dna
polymeras
substrat
prefer
cellular
substrat
cidofovir
possess
vitro
activ
adv
serotyp
prospect
control
trial
conduct
use
cidofovir
adv
infect
efficaci
remain
uncertain
data
come
nonrandom
seri
case
report
mostli
hematopoiet
stem
cell
transplant
hsct
recipi
hsctr
variou
site
infect
includ
cystiti
enter
vari
result
includ
failur
well
clearanc
viremia
possibl
mortal
benefit
monitor
adv
pcr
viral
load
may
help
assess
recoveri
although
case
report
also
report
appar
earli
clinic
virolog
improv
subsequ
respiratori
failur
death
center
particularli
care
pediatr
hsctr
may
perform
regular
adv
blood
pcr
preemptiv
monitor
initi
cidofovir
onset
viremia
tri
prevent
diseas
cidofovir
must
administ
intraven
bioavail
poor
dose
taken
intracellularli
addit
cidofovir
treatment
frequent
associ
sever
nephrotox
even
use
recommend
intraven
normal
salin
hydrat
renoprotect
agent
probenecid
usual
dose
mgkgwk
week
induct
therapi
follow
everi
week
care
monitor
renal
function
altern
dose
mgkg
three
time
weekli
brincidofovir
bcv
chimerix
durham
nc
cidofovir
deriv
lipid
moieti
augment
cellular
uptak
drug
intracellular
cidofovir
releas
easili
get
remov
cell
vitro
activ
numer
doublestrand
dna
virus
unlik
cidofovir
substrat
organ
anion
transport
caus
cidofovir
accumul
renal
tubul
bcv
lack
sever
nephrotox
cidofovir
bcv
receiv
fast
track
statu
fda
adv
infect
enrol
recent
complet
phase
clinic
trial
bcv
sever
cohort
hsctr
asymptomat
limit
adv
infect
hsctr
dissemin
adv
infect
immunocompromis
patient
adv
infect
advis
studi
primari
outcom
studi
mortal
openlabel
nonrandom
studi
includ
patient
age
month
year
bcv
administ
twice
week
week
preliminari
data
hsctr
demonstr
mix
result
improv
outcom
pediatr
patient
compar
adult
dissemin
infect
mortal
vs
mortal
respect
rapid
declin
viral
load
note
mani
patient
well
improv
overal
surviv
among
antivir
respons
howev
bcv
discontinu
due
advers
event
primarili
gastrointestin
pediatr
adult
subject
differ
surviv
treat
bcv
compar
histor
control
find
investig
believ
due
baselin
differ
two
cohort
florescu
colleagu
report
safeti
efficaci
bcv
salvag
therapi
immunocompromis
patient
sever
adv
infect
note
nine
patient
show
virolog
respons
week
patient
longer
surviv
compar
exhibit
viral
respons
day
vs
day
rbv
guanosin
analog
activ
dna
rna
virus
data
regard
efficaci
adv
infect
equivoc
limit
small
number
case
report
appear
vitro
activ
subgroup
c
serotyp
although
serotyp
analysi
typic
perform
clinic
sampl
ganciclovir
gcv
vitro
activ
adv
howev
prevent
adv
infect
among
patient
receiv
cmv
prophylaxi
gcv
valganciclovir
numer
report
literatur
cite
use
intraven
immunoglobulin
ivig
part
therapi
viral
infect
immunocompromis
patient
although
hypogammaglobulinemia
associ
increas
risk
opportunist
infect
noell
find
effect
hypogammaglobulinemia
communityacquir
rvi
cohort
lung
transplant
recipi
infect
note
patient
due
adv
reconstitut
immun
system
appear
import
overcom
adv
infect
form
immunotherapi
includ
transfer
advspecif
lymphocyt
investig
rsv
envelop
singlestrand
rna
paramyxoviru
respons
season
annual
epidem
worldwid
although
may
prolong
season
temper
climat
transmiss
occur
inhal
infecti
droplet
contact
infecti
fomit
emphas
import
appropri
infect
control
practic
especi
among
hospit
sotr
rsv
common
caus
childhood
acut
urti
lrti
highest
preval
among
children
less
year
age
incid
rsv
infect
sotr
unclear
report
literatur
rang
report
less
rsv
infect
may
occur
time
posttranspl
recent
report
found
mean
onset
year
sot
rsv
infect
typic
manifest
urti
sotr
cough
predomin
symptom
follow
dyspnea
fever
rsv
infect
progress
lrti
sotr
figur
b
addit
sotr
rsv
infect
may
difficulti
clear
infect
due
immunosuppress
result
prolong
viral
shed
mechan
ventil
requir
sotr
rsv
infect
mortal
popul
even
absenc
antivir
therapi
rel
low
publish
seri
note
one
seri
appreci
rsvrelat
mortal
note
overal
mortal
among
sotr
year
sot
compar
among
sotr
within
year
sot
limit
treatment
data
rsv
sotr
similar
adv
infect
primari
therapi
consist
support
care
reduct
immunosuppress
rbv
nucleosid
analog
demonstr
vitro
activ
rsv
aerosol
rbv
fdaapprov
rsv
treatment
howev
major
publish
clinic
data
immunocompromis
patient
hsctr
shown
decreas
progress
lrti
given
patient
urti
among
sotr
experi
rbv
lung
transplant
recipi
earli
report
aerosol
rbv
rsv
infect
lung
sotr
larg
describ
success
outcom
given
lack
compar
report
unknown
patient
would
respond
without
treatment
larger
case
seri
liu
et
al
describ
episod
rsv
among
lung
heartlung
sotr
patient
given
aerosol
rbv
gm
everi
h
dose
methylprednisolon
mg
daili
day
one
dose
ivig
mgkg
palivizumab
mgkg
patient
urti
progress
lrti
treatment
episod
requir
mechan
ventil
advers
effect
note
one
patient
die
worsen
preexist
liver
failur
unrel
rsv
infect
averag
valu
declin
time
infect
significantli
differ
baselin
month
treatment
inhal
rbv
difficult
administ
must
given
small
particl
nebul
dose
gm
daili
aerosol
continu
h
gm
everi
h
h
time
patient
confin
oxygen
hood
drugscaveng
tent
protect
healthcar
worker
patient
rbv
exposur
due
teratogen
potenti
addit
logist
complic
administr
drug
associ
seriou
toxic
hemolyt
anemia
intraven
iv
oral
po
rbv
may
given
altern
aerosol
rbv
glanvil
et
al
gave
iv
rbv
mgkg
three
divid
dose
day
follow
mgkg
three
divid
dose
lung
sotr
rsv
lrti
rbv
given
combin
prednisolon
mgkgday
mg
wean
mg
everi
day
baselin
steroid
dose
treatment
continu
repeat
nasopharyng
swab
neg
rsv
patient
requir
mechan
ventil
mortal
group
investig
gave
aforement
iv
load
dose
rbv
follow
po
rbv
mgkg
two
divid
dose
round
nearest
mg
lung
sotr
episod
rsv
lrti
median
durat
therapi
day
rbv
given
combin
prednisolon
mgkgday
taper
iv
studi
worsen
anemia
note
episod
among
patient
preexist
anemia
de
novo
anemia
episod
patient
requir
mechan
ventil
infectionrel
mortal
although
four
late
death
unrel
infect
one
two
patient
respect
newonset
bo
month
afterward
author
report
compar
outcom
po
rbv
peleaz
et
al
gave
po
rbv
mgkg
three
divid
dose
day
methylprednisolon
mgkgday
day
five
lung
sotr
patient
requir
mechan
ventil
mortal
one
patient
develop
mild
anemia
requir
treatment
larger
cohort
fuehner
et
al
describ
lung
heartlung
sotr
paramyxoviru
infect
includ
rsv
infect
half
patient
lrti
patient
receiv
po
rbv
mgkgday
two
divid
dose
day
outcom
result
pool
virus
rsv
piv
human
metapneumoviru
hmpv
infect
graft
function
recoveri
day
common
among
rbv
recipi
compar
receiv
support
care
vs
p
newonset
bo
occur
less
frequent
rbv
group
vs
p
high
rate
rbv
recipi
requir
prematur
drug
discontinu
due
advers
effect
hemolysi
renal
failur
nausea
li
et
al
compar
outcom
six
lung
sotr
receiv
po
rbv
mg
time
daili
lung
sotr
receiv
aerosol
rbv
gm
h
rsv
infect
patient
group
lrti
signific
differ
outcom
base
rout
administr
recent
cohort
studi
report
outcom
rbv
treatment
rsv
infect
among
nonlung
sotr
arizaheredia
et
al
describ
experi
sotr
kidney
liver
lung
transplant
recipi
rsv
infect
eight
lrti
given
either
aerosol
gm
h
po
rbv
dose
mgday
two
three
divid
dose
three
patient
lrti
also
receiv
palivizumab
two
also
receiv
ivig
one
patient
urti
receiv
po
rbv
although
requir
mechan
ventil
mortal
associ
infect
subsequ
investig
given
po
aerosol
rbv
nonlung
sotr
rsv
infect
number
rel
small
report
pool
lung
sotr
andor
hsctr
make
difficult
determin
drug
util
nonlung
sotr
recent
metaanalysi
gross
et
al
pool
data
among
popul
receiv
po
rbv
rvi
mortal
among
lung
sotr
receiv
po
rbv
hemolysi
rang
sever
mild
anemia
sever
hemolyt
anemia
lactic
acidosi
common
side
effect
occur
po
rbv
recipi
therapi
prematur
discontinu
due
advers
effect
despit
limit
data
support
efficaci
rbv
sotr
oral
inhal
rbv
still
commonli
employ
sotr
urti
lrti
rsv
infect
especi
lung
sotr
expert
recommend
consid
addit
antibodi
prepar
rbv
without
corticosteroid
sever
rsv
infect
sotr
although
limit
data
support
recommend
describ
small
number
case
seri
report
use
ivig
andor
palivizumab
combin
rbv
antibodi
therapi
studi
standalon
treatment
remov
market
due
introduct
palivizumab
monoclon
antibodi
rsv
fusion
f
protein
fdaapprov
prophylaxi
rsv
highrisk
infant
rsv
season
liu
et
al
azizaheredia
et
al
report
give
palivizumab
combin
rbv
ivig
andor
methylprednisolon
grodin
et
al
report
success
treatment
heart
transplant
recipi
receiv
one
dose
palivizumab
mgkg
mg
combin
aerosol
rbv
ivig
methylprednisolon
palivizumab
prophylaxi
frequent
given
outsid
rsv
season
pediatr
sotr
center
give
infant
month
infant
month
although
studi
indic
motavizumab
medimmun
llcastrazeneca
wilmington
de
secondgener
human
monoclon
antibodi
higher
affin
rsv
f
protein
greater
neutral
capac
palivizumab
compar
palivizumab
rsv
prophylaxi
highrisk
children
motavizumab
demonstr
fewer
rsvassoci
hospit
decreas
outpati
rsv
lrti
concern
increas
nonfat
hypersensit
reaction
led
fda
deni
drug
licens
approv
develop
indic
ceas
recent
report
describ
use
hightit
antirsv
neutral
antibodi
adma
biolog
inc
ramsey
nj
treatment
patient
hematolog
malign
hematopoiet
stem
cell
transplant
rsv
lrti
eleven
patient
surviv
survivor
shorter
time
rsv
diagnosi
initi
presatovir
gilead
scienc
inc
foster
citi
ca
potent
select
rsv
fusion
inhibitor
current
studi
phase
placebocontrol
rct
lung
sotr
rsv
infect
janssen
research
develop
llc
raritan
nj
nucleosid
inhibitor
rsv
rna
polymeras
inhibit
rsv
replic
vitro
effect
healthi
adult
inocul
studi
treatment
associ
rapid
rsv
clearanc
decreas
diseas
sever
compar
placebo
treatment
studi
random
placebocontrol
phase
trial
adult
hospit
rsv
infect
alnylam
pharmaceut
cambridg
small
interf
rna
direct
mrna
rsv
nucleocapsid
n
protein
rna
interfer
therapi
eightyf
healthi
volunt
experiment
infect
wildtyp
rsv
random
receiv
nasal
spray
placebo
day
day
rsv
inocul
proport
cultureconfirm
rsv
infect
among
placebo
activ
drug
recipi
respect
p
similar
safe
profil
medic
sinc
studi
lung
sotr
rsv
infect
subject
random
receiv
activ
drug
placebo
daili
day
primari
outcom
progress
bo
found
recipi
compar
placebo
control
p
treatment
effect
enhanc
start
less
day
symptom
onset
independ
rbv
administr
howev
compound
longer
develop
hmpv
envelop
singlestrand
rna
viru
paramyxoviru
famili
hmpv
newli
discov
recent
found
serolog
studi
present
popul
year
prior
initi
describ
caus
urti
lrti
immunocompet
children
year
age
known
caus
infect
older
adult
immunocompromis
individu
season
similar
influenza
retrospect
studi
lung
transplant
recipi
found
hmpv
account
rvi
addit
although
mani
studi
report
mortal
due
hmpv
infect
among
transplant
recipi
also
descript
fatal
hmpv
lrti
despit
treatment
rbv
ivig
shahda
report
death
relat
hmpv
infect
two
four
lung
transplant
recipi
wors
lung
function
two
surviv
recipi
allograft
reject
report
sotr
hmpv
infect
approv
drug
treatment
hmpv
respiratori
infect
support
therapi
main
treatment
although
rbv
alon
ivig
given
sotr
shahda
report
recoveri
two
hsctr
hmpv
pneumonia
transplant
oral
aerosol
rbv
ivig
kitanovski
report
rapid
recoveri
hmpv
pneumonia
immunocompromis
treatment
oral
rbv
ivig
howev
chu
et
al
report
mortal
due
hmpv
pneumonia
cohort
despit
therapi
sponsor
clinic
trial
underway
address
therapi
hmpv
immunocompromis
patient
monoclon
antibodi
potenti
effect
clinic
hmpv
infect
develop
similar
rsv
hmpv
piv
envelop
singlestrand
rna
paramyxoviru
classifi
four
type
type
tend
circul
fall
winter
circul
yearround
highest
incid
late
spring
summer
uncommon
figur
significantli
fewer
data
piv
infect
sotr
compar
hsct
recipi
data
sotr
lung
transplant
recipi
review
piv
infect
lung
transplant
recipi
year
reveal
infect
occur
median
year
transplant
rang
year
respiratori
failur
develop
bo
infect
caus
type
also
caus
major
infect
hsctr
urti
common
manifest
although
progress
lrti
result
fatal
infect
mortal
review
lung
transplant
recipi
note
piv
infect
may
seriou
pediatr
sotr
well
lung
sotr
age
respiratori
virus
piv
strongli
associ
develop
bo
lung
sotr
support
care
mainstay
piv
treatment
rbv
demonstr
vitro
activ
piv
use
monotherapi
combin
ivig
corticosteroid
treat
lung
sotr
piv
infect
rel
small
retrospect
cohort
studi
lung
transplant
recipi
outcom
data
pool
paramyxoviru
rbv
associ
variabl
respons
novel
recombin
sialidas
fusion
protein
administ
oral
inhal
ansun
biopharma
san
diego
ca
vitro
activ
piv
bind
respiratori
epitheli
cell
remov
cellsurfac
sialic
acid
residu
necessari
piv
attach
cell
entri
demonstr
efficaci
piv
compassionateus
protocol
conduct
hsctr
eleven
patient
hypox
day
complet
clinic
respons
partial
respons
also
three
death
addit
two
anecdot
report
success
use
lung
sotr
drug
current
studi
phase
clinic
trial
treatment
piv
sotr
hsctr
final
similar
adv
immunotherapi
mclaughlin
et
al
gener
cell
healthi
donor
use
yet
report
human
human
rhinovirus
hrv
member
enteroviru
genu
henc
known
respiratori
enterovirus
nonenvelop
singlestrand
rna
picornavirus
capabl
caus
urti
lrti
display
peak
incid
spring
fall
highest
occurr
children
may
act
reservoir
hrv
frequent
caus
common
cold
children
adult
well
frequent
caus
rvi
sotr
hrv
histor
classifi
two
speci
hrva
hrvb
recent
discoveri
new
speci
hrvc
hrvc
sinc
deem
preval
hrv
speci
although
still
commonli
caus
urti
children
also
caus
lrti
adult
epidemiolog
hrvc
sotr
well
describ
literatur
common
manifest
hrv
infect
urti
symptom
often
absent
milder
compar
piv
rsv
infect
role
hrv
lrti
debat
given
frequenc
detect
asymptomat
person
review
bronchoalveolar
lavag
specimen
lung
transplant
recipi
show
detect
rate
compar
approxim
immunocompromis
individu
immunocompet
patient
demonstr
high
rate
lrti
lung
transplant
recipi
howev
also
high
rate
coinfect
viral
nonvir
pathogen
patient
minor
patient
sign
symptom
pneumonia
one
lung
transplant
recipi
hrv
isol
singl
agent
experi
respiratori
failur
approv
antivir
treatment
rhinovirus
pleconaril
merck
sharp
dohm
corp
kenilworth
nj
bind
hrv
capsid
protein
surround
rna
genom
interfer
hrv
bind
cellular
receptor
shown
broad
antienterovir
activ
hayden
et
al
report
two
random
doubleblind
studi
pleconaril
reduc
durat
ill
day
among
adult
hrv
infect
although
data
infant
reveal
drug
accumul
increas
advers
effect
fda
approv
treatment
common
cold
reject
due
safeti
issu
concern
antivir
resist
subsequ
drug
develop
nasal
spray
aim
reduc
common
cold
symptom
asthma
exacerb
follow
hrv
infect
oral
formul
treatment
enterovir
sepsi
neonat
vapendavir
aviragen
therapeut
alpharetta
ga
anoth
capsidbind
agent
found
potent
pleconaril
develop
treatment
hrv
phase
studi
adult
hrv
asthma
recent
complet
drug
studi
sotr
recombin
human
recent
shown
improv
heal
clearanc
time
among
children
hand
foot
mouth
diseas
caus
subcutan
studi
among
patient
hypogammaglobulinemia
hrv
infect
inhal
synairgen
research
ltd
southampton
uk
studi
random
trial
patient
asthma
hrv
infect
assess
whether
reduc
virusrel
asthma
exacerb
patient
receiv
inhal
placebo
within
h
develop
cold
symptom
treatment
signific
effect
prevent
attenu
asthma
symptom
entir
cohort
subanalysi
difficulttotreat
asthmat
show
treatment
associ
improv
asthma
control
atopix
therapeut
ltd
abingdon
oxon
uk
chemoattract
receptor
homolog
cell
antagonist
decreas
cell
eosinophil
chemotaxi
inhibit
releas
cytokin
design
improv
lung
function
patient
eosinophil
asthma
studi
phase
trial
adult
asthma
hrv
infect
omalizumab
human
antibodi
bind
free
ige
approv
use
treatment
asthma
studi
mild
asthmat
hrv
infect
addit
compound
vitro
activ
viral
target
hrv
proteas
helicas
rna
polymeras
investig
treatment
hrv
infect
human
coronavirus
hcov
envelop
rna
virus
tend
occur
season
manner
similar
clinic
present
hrv
infect
gener
result
selflimit
diseas
may
progress
lrti
young
children
older
adult
common
type
hcov
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
novel
coronavirus
respons
recent
acut
respiratori
syndrom
epidem
merscov
zoonot
viru
camel
like
sourc
transmiss
epidemiolog
hcov
infect
sotr
limit
recent
report
describ
two
renal
sotr
recipi
merscov
infect
one
patient
progress
respiratori
renal
failur
die
patient
respiratori
symptom
remain
stabl
recov
infect
despit
receipt
antithymocyt
globulin
one
month
prior
antivir
licens
treatment
hcov
infect
therapi
consist
support
care
great
interest
develop
effect
treatment
merscov
given
preval
middl
east
appar
high
fatal
rate
one
review
effect
rbv
combin
merscov
report
two
public
omrani
et
al
retrospect
compar
treatment
group
patient
merscov
lrti
control
patient
receiv
support
care
patient
group
requir
mechan
ventil
day
antivir
recipi
surviv
compar
control
p
treatment
effect
longer
statist
signific
day
vs
p
altawfiq
et
al
report
case
seri
five
critic
ill
adult
receiv
po
rbv
osteltamivir
corticosteroid
merscov
lrti
none
patient
respond
therapi
patient
die
although
median
time
admiss
rbv
interferon
day
rang
day
use
combin
report
sotr
lopinavirritonavir
approv
treatment
hiv
infect
vitro
activ
merscov
activ
marmoset
model
infect
phase
placebocontrol
studi
conduct
saudi
arabia
assess
efficaci
combin
two
drug
given
day
hospit
adult
merscov
also
phase
trial
saudi
arabia
convalesc
plasma
merscov
infect
use
plasma
obtain
patient
recent
recov
merscov
healthcar
worker
exposur
volunt
donor
adv
rsv
hmpv
piv
hrv
hcov
common
caus
noninfluenza
respiratori
infect
sotr
knowledg
epidemiolog
spectrum
pathogen
expand
use
newli
avail
rapid
molecular
diagnost
tool
rvi
may
caus
sever
morbid
respiratori
failur
may
fatal
immunocompromis
host
studi
shown
associ
rvi
longterm
allograft
dysfunct
main
therapi
mani
consist
reduct
immunosuppress
support
care
treatment
option
need
addit
research
dedic
epidemiolog
rvi
sotr
risk
factor
associ
poor
outcom
number
sotr
continu
increas
leav
larg
popul
vulner
potenti
sever
rvi
clearli
need
new
effect
nontox
antivir
compound
activ
communityacquir
respiratori
virus
articl
highlight
avail
therapi
well
compound
later
stage
develop
howev
work
need
area
sinc
clinic
avail
treatment
limit
toxic
unproven
unavail
depend
viru
question
novel
antivir
brincidofovir
highli
anticip
latter
futur
uncertain
given
mix
result
recent
studi
immunocompromis
patient
cmv
infect
adv
infect
broadspectrum
antivir
possess
activ
multipl
rvi
high
barrier
develop
resist
could
provid
great
benefit
one
major
question
clinician
face
treat
sotr
avail
antivir
cidofovir
rbv
interven
therapi
sotr
develop
lrti
respiratori
failur
advers
effect
medic
may
signific
predictor
poor
outcom
would
extrem
use
studi
shown
correl
viral
load
sever
diseas
due
rvi
work
need
identifi
viral
load
cutoff
predict
lrti
respiratori
failur
whether
quantif
upper
respiratori
tract
viral
load
predict
viral
burden
lower
respiratori
tract
note
strategi
preemptiv
therapi
adv
infect
via
monitor
quantit
viral
load
blood
advoc
allogen
hsct
recipi
strategi
yet
establish
benefici
sotr
manipul
immun
system
addit
tool
could
combat
rvi
immun
reconstitut
import
factor
recoveri
infect
organ
transplant
note
use
specif
immunotherapi
virusspecif
cell
particularli
simultan
activ
multipl
virus
may
signific
advanc
antivir
therapi
allow
broad
applic
technolog
would
optim
cell
could
made
donor
seroneg
eg
use
cord
bloodderiv
cytotox
lymphocyt
deriv
third
parti
offtheshelf
therapi
time
inflammatori
respons
may
sometim
deleteri
rvi
rather
target
viral
protein
enzym
target
host
protein
involv
pathogenesi
rvi
infect
addit
potenti
treatment
approach
antagonist
mention
diminish
harm
immun
respons
prompt
rvi
addit
inhibitor
cyclophilin
cyclosporin
prevent
inflammatori
cytokin
product
shown
activ
hcov
develop
accur
measur
immun
function
would
also
quit
help
stratifi
sotr
highest
risk
seriou
rvi
complic
rvi
final
develop
effect
vaccin
rvi
high
prioriti
given
preval
infect
impact
immunocompet
immunocompromis
individu
